secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outset Medical, Inc. (OM)
CIK:        0001484612
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0000950170-22-013586
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outset Medical Q2 revenue $25.1M flat; FDA clears Tablo for home use; FY22 guidance $105-110M
--------------------------------------------------------------------------------

- Q2 revenue $25.1M flat YoY; net loss ($43.8M) vs ($30.2M); GAAP EPS ($0.92).
- FDA cleared 510(k) for Tablo home use; shipments resumed after voluntary hold.
- FY 2022 guidance: revenue $105M-$110M (2-7% growth) citing staffing & inflation pressures.
- Gross margin improved to 15.1% from 4.2% YoY, but operating expenses rose to $47.5M vs $31.0M.
- Cash $295.4M as of June 30; non-GAAP net loss per share ($0.77).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484612/000095017022013586/0000950170-22-013586-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484612/000095017022013586/om-20220801.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-013586

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer